Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 422

1.

Evaluation of a health service adopting proactive approach to reduce high risk of lung cancer: The Liverpool Healthy Lung Programme.

Ghimire B, Maroni R, Vulkan D, Shah Z, Gaynor E, Timoney M, Jones L, Arvanitis R, Ledson M, Lukehirst L, Rutherford P, Clarke F, Gardner K, Marcus MW, Hill S, Fideo D, Mason S, Smith SG, Quaife SL, Fitzgerald K, Poirier V, Duffy SW, Field JK.

Lung Cancer. 2019 Aug;134:66-71. doi: 10.1016/j.lungcan.2019.05.026. Epub 2019 May 29.

PMID:
31319997
2.

Long-term excess risk of breast cancer after a single breast density measurement.

Rebolj M, Blyuss O, Chia KS, Duffy SW.

Eur J Cancer. 2019 Aug;117:41-47. doi: 10.1016/j.ejca.2019.05.009. Epub 2019 Jun 21.

3.

Imaging Biomarkers as Predictors for Breast Cancer Death.

Wu WY, Tabar L, Tot T, Fann CY, Yen AM, Chen SL, Chiu SY, Ku MM, Hsu CY, Beckmann KR, Smith RA, Duffy SW, Chen HH.

J Oncol. 2019 Apr 10;2019:2087983. doi: 10.1155/2019/2087983. eCollection 2019.

4.

Probability of cancer in lung nodules using sequential volumetric screening up to 12 months: the UKLS trial.

Marcus MW, Duffy SW, Devaraj A, Green BA, Oudkerk M, Baldwin D, Field J.

Thorax. 2019 Aug;74(8):761-767. doi: 10.1136/thoraxjnl-2018-212263. Epub 2019 Apr 26.

PMID:
31028232
5.

Towards evidence-based follow-up intervals for breast cancer survivors: Estimates of the preclinical detectable phase of contralateral second breast cancer.

Aarts AMWM, Duffy SW, Geurts SME, Vulkan DP, Houssami N, Zappa M, Nagtegaal ID, Verbeek ALM, Broeders MJM.

Breast. 2019 Jun;45:70-74. doi: 10.1016/j.breast.2019.03.003. Epub 2019 Mar 8.

PMID:
30884341
6.

Reply to The incidence of fatal breast cancer measures the increased effectiveness of therapy in women participating in mammography screening.

Duffy SW, Smith RA, Tabár L, Dean PB, Chen TH.

Cancer. 2019 Jun 15;125(12):2130-2131. doi: 10.1002/cncr.32007. Epub 2019 Feb 12. No abstract available.

PMID:
30747993
7.

Faecal immunochemical tests versus colonoscopy for post-polypectomy surveillance: an accuracy, acceptability and economic study.

Atkin W, Cross AJ, Kralj-Hans I, MacRae E, Piggott C, Pearson S, Wooldrage K, Brown J, Lucas F, Prendergast A, Marchevsky N, Patel B, Pack K, Howe R, Skrobanski H, Kerrison R, Swart N, Snowball J, Duffy SW, Morris S, von Wagner C, Halloran S.

Health Technol Assess. 2019 Jan;23(1):1-84. doi: 10.3310/hta23010.

8.

Test sensitivity of mammography and mean sojourn time over 40 years of breast cancer screening in Nijmegen (The Netherlands).

Aarts AMWM, Duffy SW, Geurts SME, Vulkan DP, Otten JDM, Hsu C-Y, Chen THH, Verbeek ALM, Broeders MJM.

J Med Screen. 2018 Dec 12:969141318814869. doi: 10.1177/0969141318814869. [Epub ahead of print]

PMID:
30541383
9.

Faecal immunochemical tests (FIT) versus colonoscopy for surveillance after screening and polypectomy: a diagnostic accuracy and cost-effectiveness study.

Cross AJ, Wooldrage K, Robbins EC, Kralj-Hans I, MacRae E, Piggott C, Stenson I, Prendergast A, Patel B, Pack K, Howe R, Swart N, Snowball J, Duffy SW, Morris S, von Wagner C, Halloran SP, Atkin WS.

Gut. 2018 Dec 11. pii: gutjnl-2018-317297. doi: 10.1136/gutjnl-2018-317297. [Epub ahead of print]

10.

Risk stratification in breast screening: A word of caution.

Duffy SW.

J Med Screen. 2019 Jun;26(2):57-58. doi: 10.1177/0969141318813387. Epub 2018 Nov 18. No abstract available.

PMID:
30449245
11.

The incidence of fatal breast cancer measures the increased effectiveness of therapy in women participating in mammography screening.

Tabár L, Dean PB, Chen TH, Yen AM, Chen SL, Fann JC, Chiu SY, Ku MM, Wu WY, Hsu CY, Chen YC, Beckmann K, Smith RA, Duffy SW.

Cancer. 2019 Feb 15;125(4):515-523. doi: 10.1002/cncr.31840. Epub 2018 Nov 8.

12.

Reply to 'Comment on 'Addition of ultrasound to mammography in the case of dense breast tissue: systematic review and meta-analysis".

Rebolj M, Brentnall A, Duffy SW.

Br J Cancer. 2018 Nov;119(11):1444. doi: 10.1038/s41416-018-0247-y. Epub 2018 Nov 9. No abstract available.

PMID:
30410058
13.

The impact of mammography screening programmes on incidence of advanced breast cancer in Europe: a literature review.

Broeders MJM, Allgood P, Duffy SW, Hofvind S, Nagtegaal ID, Paci E, Moss SM, Bucchi L.

BMC Cancer. 2018 Sep 3;18(1):860. doi: 10.1186/s12885-018-4666-1. Review.

14.

Lung cancer CT screening: are we ready to consider screening biennially in a subgroup of low-risk individuals?

Field JK, Duffy SW.

Thorax. 2018 Nov;73(11):1006-1007. doi: 10.1136/thoraxjnl-2018-211814. Epub 2018 Jun 28. No abstract available.

PMID:
29954858
15.

Trends in lung cancer emergency presentation in England, 2006-2013: is there a pattern by general practice?

Maringe C, Pashayan N, Rubio FJ, Ploubidis G, Duffy SW, Rachet B, Raine R.

BMC Cancer. 2018 May 31;18(1):615. doi: 10.1186/s12885-018-4476-5.

16.

Patient selection for future lung cancer computed tomography screening programmes: lessons learnt post National Lung Cancer Screening Trial.

Field JK, Duffy SW, Baldwin DR.

Transl Lung Cancer Res. 2018 Apr;7(Suppl 2):S114-S116. doi: 10.21037/tlcr.2018.03.12. No abstract available.

17.

Addition of ultrasound to mammography in the case of dense breast tissue: systematic review and meta-analysis.

Rebolj M, Assi V, Brentnall A, Parmar D, Duffy SW.

Br J Cancer. 2018 Jun;118(12):1559-1570. doi: 10.1038/s41416-018-0080-3. Epub 2018 May 8.

18.

Association between Screening Mammography Recall Rate and Interval Cancers in the UK Breast Cancer Service Screening Program: A Cohort Study.

Burnside ES, Vulkan D, Blanks RG, Duffy SW.

Radiology. 2018 Jul;288(1):47-54. doi: 10.1148/radiol.2018171539. Epub 2018 Apr 3.

19.

Low-dose CT for lung cancer screening - Authors' reply.

Field JK, Heuvelmans MA, Devaraj A, Heussel CP, Baldwin DR, Vliegenthart R, Duffy SW, Oudkerk M.

Lancet Oncol. 2018 Mar;19(3):e135-e136. doi: 10.1016/S1470-2045(18)30122-0. No abstract available.

PMID:
29508758
20.

European position statement on lung cancer screening.

Oudkerk M, Devaraj A, Vliegenthart R, Henzler T, Prosch H, Heussel CP, Bastarrika G, Sverzellati N, Mascalchi M, Delorme S, Baldwin DR, Callister ME, Becker N, Heuvelmans MA, Rzyman W, Infante MV, Pastorino U, Pedersen JH, Paci E, Duffy SW, de Koning H, Field JK.

Lancet Oncol. 2017 Dec;18(12):e754-e766. doi: 10.1016/S1470-2045(17)30861-6. Review.

PMID:
29208441
21.

Mammographic density and breast cancer risk in breast screening assessment cases and women with a family history of breast cancer.

Duffy SW, Morrish OWE, Allgood PC, Black R, Gillan MGC, Willsher P, Cooke J, Duncan KA, Michell MJ, Dobson HM, Maroni R, Lim YY, Purushothaman HN, Suaris T, Astley SM, Young KC, Tucker L, Gilbert FJ.

Eur J Cancer. 2018 Jan;88:48-56. doi: 10.1016/j.ejca.2017.10.022. Epub 2017 Nov 27.

22.

Fear, family and the placing of emotion: Black women's responses to a breast cancer awareness intervention.

Brown T, Dyck I, Greenhough B, Raven-Ellison M, Dembinsky M, Ornstein M, Duffy SW.

Soc Sci Med. 2017 Dec;195:90-96. doi: 10.1016/j.socscimed.2017.10.037. Epub 2017 Nov 20.

PMID:
29156250
23.

Effect of Mammography Screening on Mortality by Histological Grade.

Tabar L, Chen TH, Yen AM, Chen SL, Fann JC, Chiu SY, Ku MMS, Wu WY, Hsu CY, Chen YY, Beckmann K, Smith RA, Duffy SW.

Cancer Epidemiol Biomarkers Prev. 2018 Feb;27(2):154-157. doi: 10.1158/1055-9965.EPI-17-0487. Epub 2017 Nov 17.

24.

Impact of radiographer immediate reporting of chest X-rays from general practice on the lung cancer pathway (radioX): study protocol for a randomised control trial.

Woznitza N, Devaraj A, Janes SM, Duffy SW, Bhowmik A, Rowe S, Piper K, Maughn S, Baldwin DR.

Trials. 2017 Nov 6;18(1):521. doi: 10.1186/s13063-017-2268-x.

25.

Breast Cancer Screening in Denmark.

Chen THH, Duffy SW.

Ann Intern Med. 2017 Oct 3;167(7):523-524. doi: 10.7326/L17-0267. No abstract available.

PMID:
28973197
26.

Reducing the socioeconomic gradient in uptake of the NHS bowel cancer screening Programme using a simplified supplementary information leaflet: a cluster-randomised trial.

Smith SG, Wardle J, Atkin W, Raine R, McGregor LM, Vart G, Morris S, Duffy SW, Moss S, Hackshaw A, Halloran S, Kralj-Hans I, Howe R, Snowball J, Handley G, Logan RF, Rainbow S, Smith S, Thomas M, Counsell N, von Wagner C.

BMC Cancer. 2017 Aug 14;17(1):543. doi: 10.1186/s12885-017-3512-1.

27.

Colorectal adenomas, surveillance, and cancer - Authors' reply.

Atkin W, Wooldrage K, Sasieni P, Duffy SW, Cross AJ.

Lancet Oncol. 2017 Aug;18(8):e428. doi: 10.1016/S1470-2045(17)30532-6. Epub 2017 Jul 26. No abstract available.

28.

The impact of trained radiographers as concurrent readers on performance and reading time of experienced radiologists in the UK Lung Cancer Screening (UKLS) trial.

Nair A, Screaton NJ, Holemans JA, Jones D, Clements L, Barton B, Gartland N, Duffy SW, Baldwin DR, Field JK, Hansell DM, Devaraj A.

Eur Radiol. 2018 Jan;28(1):226-234. doi: 10.1007/s00330-017-4903-z. Epub 2017 Jun 22.

29.

The clinical effectiveness of different surveillance strategies to prevent colorectal cancer in people with intermediate-grade colorectal adenomas: a retrospective cohort analysis, and psychological and economic evaluations.

Atkin W, Brenner A, Martin J, Wooldrage K, Shah U, Lucas F, Greliak P, Pack K, Kralj-Hans I, Thomson A, Perera S, Wood J, Miles A, Wardle J, Kearns B, Tappenden P, Myles J, Veitch A, Duffy SW.

Health Technol Assess. 2017 Apr;21(25):1-536. doi: 10.3310/hta21250.

30.

Screening organization and recall rate in a regional breast screening programme.

Beruchashwili T, Gvamichava R, Duffy SW.

J Med Screen. 2018 Mar;25(1):55-56. doi: 10.1177/0969141317704680. Epub 2017 Jun 14.

PMID:
28614990
31.

GP participation in increasing uptake in a national bowel cancer screening programme: the PEARL project.

Benton SC, Butler P, Allen K, Chesters M, Rickard S, Stanley S, Roope R, Vulkan D, Duffy SW.

Br J Cancer. 2017 Jun 6;116(12):1551-1557. doi: 10.1038/bjc.2017.129. Epub 2017 May 18.

32.

Effect of second timed appointments for non-attenders of breast cancer screening in England: a randomised controlled trial.

Allgood PC, Maroni R, Hudson S, Offman J, Turnbull AE, Peacock L, Steel J, Kirby G, Ingram CE, Somers J, Fuller C, Threlfall AG, Gabe R, Maxwell AJ, Patnick J, Duffy SW.

Lancet Oncol. 2017 Jul;18(7):972-980. doi: 10.1016/S1470-2045(17)30340-6. Epub 2017 May 15.

33.

Adenoma surveillance and colorectal cancer incidence: a retrospective, multicentre, cohort study.

Atkin W, Wooldrage K, Brenner A, Martin J, Shah U, Perera S, Lucas F, Brown JP, Kralj-Hans I, Greliak P, Pack K, Wood J, Thomson A, Veitch A, Duffy SW, Cross AJ.

Lancet Oncol. 2017 Jun;18(6):823-834. doi: 10.1016/S1470-2045(17)30187-0. Epub 2017 Apr 28.

34.

Does Reader Performance with Digital Breast Tomosynthesis Vary according to Experience with Two-dimensional Mammography?

Tucker L, Gilbert FJ, Astley SM, Dibden A, Seth A, Morel J, Bundred S, Litherland J, Klassen H, Lip G, Purushothaman H, Dobson HM, McClure L, Skippage P, Stoner K, Kissin C, Beetles U, Lim YY, Hurley E, Goligher J, Rahim R, Gagliardi TJ, Suaris T, Duffy SW.

Radiology. 2017 May;283(2):371-380. doi: 10.1148/radiol.2017151936. Epub 2017 Mar 13.

PMID:
28287917
35.

Both a stage shift and changes in stage-specific survival have contributed to reductions in breast cancer mortality.

Duffy SW, Etzioni R, Sasieni P.

Evid Based Med. 2017 Apr;22(2):76. doi: 10.1136/ebmed-2016-110632. Epub 2017 Feb 22. No abstract available.

PMID:
28228386
36.

Initiators and promoters for the occurrence of screen-detected breast cancer and the progression to clinically-detected interval breast cancer.

Yen AM, Wu WY, Tabar L, Duffy SW, Smith RA, Chen HH.

J Epidemiol. 2017 Mar;27(3):98-106. doi: 10.1016/j.je.2016.10.003. Epub 2016 Nov 28.

37.

Breast-Cancer Tumor Size and Screening Effectiveness.

Brentnall AR, Duffy SW, Cuzick J.

N Engl J Med. 2017 Jan 5;376(1):94. doi: 10.1056/NEJMc1614282. No abstract available.

PMID:
28052231
38.

Optimum low dose CT screening interval for lung cancer: the answer from NELSON?

Baldwin DR, Duffy SW, Devaraj A, Field JK.

Thorax. 2017 Jan;72(1):6-7. doi: 10.1136/thoraxjnl-2016-209011. Epub 2016 Oct 21. No abstract available.

PMID:
27974632
39.

A national cluster-randomised controlled trial to examine the effect of enhanced reminders on the socioeconomic gradient in uptake in bowel cancer screening.

Raine R, Moss SM, von Wagner C, Atkin W, Hans IK, Howe R, Solmi F, Morris S, Counsell N, Hackshaw A, Halloran S, Handley G, Logan RF, Rainbow S, Smith S, Snowball J, Seaman H, Thomas M, Smith SG, McGregor LM, Vart G, Wardle J, Duffy SW.

Br J Cancer. 2016 Dec 6;115(12):1479-1486. doi: 10.1038/bjc.2016.365. Epub 2016 Nov 22.

40.

Rapid review of evaluation of interventions to improve participation in cancer screening services.

Duffy SW, Myles JP, Maroni R, Mohammad A.

J Med Screen. 2017 Sep;24(3):127-145. doi: 10.1177/0969141316664757. Epub 2016 Oct 17.

41.

Implementation planning for lung cancer screening: five major challenges.

Field JK, Duffy SW, Devaraj A, Baldwin DR.

Lancet Respir Med. 2016 Sep;4(9):685-687. doi: 10.1016/S2213-2600(16)30233-8. No abstract available.

PMID:
27599242
42.

Is cancer survival associated with cancer symptom awareness and barriers to seeking medical help in England? An ecological study.

Niksic M, Rachet B, Duffy SW, Quaresma M, Møller H, Forbes LJ.

Br J Cancer. 2016 Sep 27;115(7):876-86. doi: 10.1038/bjc.2016.246. Epub 2016 Aug 18.

43.

Long-term psychosocial outcomes of low-dose CT screening: results of the UK Lung Cancer Screening randomised controlled trial.

Brain K, Lifford KJ, Carter B, Burke O, McRonald F, Devaraj A, Hansell DM, Baldwin D, Duffy SW, Field JK.

Thorax. 2016 Nov;71(11):996-1005. doi: 10.1136/thoraxjnl-2016-208283. Epub 2016 Jul 28.

44.

Comparing the performance of trained radiographers against experienced radiologists in the UK lung cancer screening (UKLS) trial.

Nair A, Gartland N, Barton B, Jones D, Clements L, Screaton NJ, Holemans JA, Duffy SW, Field JK, Baldwin DR, Hansell DM, Devaraj A.

Br J Radiol. 2016 Oct;89(1066):20160301. doi: 10.1259/bjr.20160301. Epub 2016 Jul 27.

45.

Ovarian cancer screening: UKCTOCS trial.

Sasieni PD, Duffy SW, Cuzick J.

Lancet. 2016 Jun 25;387(10038):2602. doi: 10.1016/S0140-6736(16)30847-9. No abstract available.

PMID:
27353820
46.

The UK Lung Cancer Screening Trial: a pilot randomised controlled trial of low-dose computed tomography screening for the early detection of lung cancer.

Field JK, Duffy SW, Baldwin DR, Brain KE, Devaraj A, Eisen T, Green BA, Holemans JA, Kavanagh T, Kerr KM, Ledson M, Lifford KJ, McRonald FE, Nair A, Page RD, Parmar MK, Rintoul RC, Screaton N, Wald NJ, Weller D, Whynes DK, Williamson PR, Yadegarfar G, Hansell DM.

Health Technol Assess. 2016 May;20(40):1-146. doi: 10.3310/hta20400.

47.

Impact of Screening on Breast Cancer Mortality-Response.

Massat NJ, Dibden A, Parmar D, Cuzick J, Sasieni PD, Duffy SW.

Cancer Epidemiol Biomarkers Prev. 2016 May;25(5):873. doi: 10.1158/1055-9965.EPI-16-0170. No abstract available.

48.

A Pragmatic Approach to Determine Components of Optimal Screening Mammography Practice.

Burnside ES, Sickles EA, Duffy SW.

JAMA. 2016 May 10;315(18):1951-3. doi: 10.1001/jama.2016.4530. No abstract available.

PMID:
27163983
49.

Incorporating epistasis interaction of genetic susceptibility single nucleotide polymorphisms in a lung cancer risk prediction model.

Marcus MW, Raji OY, Duffy SW, Young RP, Hopkins RJ, Field JK.

Int J Oncol. 2016 Jul;49(1):361-70. doi: 10.3892/ijo.2016.3499. Epub 2016 Apr 25.

50.

The Lung Screen Uptake Trial (LSUT): protocol for a randomised controlled demonstration lung cancer screening pilot testing a targeted invitation strategy for high risk and 'hard-to-reach' patients.

Quaife SL, Ruparel M, Beeken RJ, McEwen A, Isitt J, Nolan G, Sennett K, Baldwin DR, Duffy SW, Janes SM, Wardle J.

BMC Cancer. 2016 Apr 20;16:281. doi: 10.1186/s12885-016-2316-z.

Supplemental Content

Loading ...
Support Center